World's Best Scientists 2026 revealed!
Ronald M. Bukowski

Ronald M. Bukowski

D-Index & Metrics

Medicine

D-Index
109
Citations
57428
World Ranking
5684
National Ranking
3061

Overview

Ronald M. Bukowski is affiliated with the Cleveland Clinic in the United States. Their research primarily focuses on medical fields related to cancer, with a strong emphasis on renal cell carcinoma treatment and prostate cancer research.

The main fields of study associated with Ronald M. Bukowski include Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, their work further specializes in subfields such as Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Endocrinology, Diabetes and Metabolism.

Their research topics cover several key areas:

  • Renal cell carcinoma treatment
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Hormonal and reproductive studies

Ronald M. Bukowski has contributed to scientific literature through publications in multiple venues:

  • Journal of Clinical Oncology
  • Clinical Genitourinary Cancer
  • Frontiers in Oncology

Key recent papers authored or co-authored by Bukowski include:

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2023, Journal of Clinical Oncology)
  • Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure (2020, Clinical Genitourinary Cancer)
  • Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer (2020, Frontiers in Oncology)

The scientist has frequently collaborated with several co-authors, including:

  • Robert A. Figlin
  • Robert J. Motzer
  • Thomas E. Hutson
  • Piotr Tomczak
  • M. Dror Michaelson

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

    Jennifer S. Ko;Arnold H. Zea;Brian I. Rini;Joanna L. Ireland

  • Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

    Tarek M. Mekhail;Rony M. Abou-Jawde;Gabriel BouMerhi;Sareena Malhi

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

    James H. Finke;Brian I Rini;Joanna Ireland;Patricia Rayman

  • Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

    Bernard Escudier;Cezary Szczylik;Thomas E. Hutson;Tomasz Demkow

  • Targeted Therapy for Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Ronald M. Bukowski

  • Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

    Olivier Rixe;Ronald M Bukowski;M Dror Michaelson;George Wilding

  • Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

    B. Escudier;C. Szczylik;T. Eisen;W. M. Stadler

  • Loss of T-Cell Receptor ζ Chain and p56lck in T-Cells Infiltrating Human Renal Cell Carcinoma

    James H. Finke;Arnold H. Zea;Jill Stanley;Dan L. Longo

  • Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

    E Van Cutsem;P M Hoff;P Harper;R M Bukowski

  • Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

    Brian I. Rini;Ila Tamaskar;Phillip Shaheen;Renee Salas

  • Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

    Toni K. Choueiri;Anne Plantade;Paul Elson;Sylvie Negrier

  • Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Toni K. Choueiri;Ulka Vaishampayan;Jonathan E. Rosenberg;Theodore F. Logan

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

Frequent Co-Authors

James H. Finke
James H. Finke Cleveland Clinic Lerner College of Medicine
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Thomas E. Hutson
Thomas E. Hutson Texas Oncology
Raymond R. Tubbs
Raymond R. Tubbs Cleveland Clinic
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Andrew C. Novick
Andrew C. Novick Cleveland Clinic
Walter M. Stadler
Walter M. Stadler University of Chicago
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Toni K. Choueiri
Toni K. Choueiri Harvard University
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always require following the traditional route of medical school. There are many related healthcare pathways available online, each offering flexibility and unique career prospects. For those who are already registered nurses, pursuing one of the cheapest rn to bsn programs can help you advance your credentials while keeping costs manageable.

If you don’t hold a nursing background but want to transition into this rewarding field, you may consider direct entry msn programs for non nurses online. These programs are specifically designed to fast-track your move into nursing and can be completed from anywhere.

Entry into the nursing profession is becoming more accessible too, with online bsn programs for non nurses offering flexible options and less competitive admissions. This is a great choice for career changers who want to start in healthcare.

Those interested in healthcare administration and support roles may look into online medical coding classes with financial aid. This growing field allows graduates to contribute to healthcare operations without direct patient care.

Best Scientists Citing Ronald M. Bukowski

Trending Scientists